Format

Send to

Choose Destination
Br J Pharmacol. 2017 Nov;174(22):4087-4098. doi: 10.1111/bph.13939. Epub 2017 Aug 11.

Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2 : a safer alternative to COX-2 inhibition.

Author information

1
INSERM U1148, Paris, France.
2
Faculty of Pharmacy, Department of Pharmacology, Istanbul University, Istanbul, Turkey.
3
Department of Infection, Immunity and Cardiovascular Disease, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK.
4
Department of Cardiovascular Surgery, Aile Hospital, Istanbul, Turkey.
5
Unit of Rheumatology, Department of Medicine Solna, Karolinska Institute and Unit of Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
6
AP-HP CHU X. Bichat, Department of Anesthesia and Intensive Care, University Paris Diderot, Sorbonne Paris-Cité, UMR-S1148, Paris, France.
7
University Paris Diderot, Sorbonne Paris-Cité, UMR-S1148, Paris, France.

Abstract

BACKGROUND AND PURPOSE:

The side effects of cyclooxygenase-2 (COX-2) inhibitors on the cardiovascular system could be associated with reduced prostaglandin (PG)I2 synthesis. Microsomal PGE synthase-1 (mPGES-1) catalyses the formation of PGE2 from COX-derived PGH2 . This enzyme is induced under inflammatory conditions and constitutes an attractive target for novel anti-inflammatory drugs. However, it is not known whether mPGES-1 inhibitors could be devoid of cardiovascular side effects. The aim of this study was to compare, in vitro, the effects of mPGES-1 and COX-2 inhibitors on vascular tone in human blood vessels.

EXPERIMENTAL APPROACH:

The vascular tone and prostanoid release from internal mammary artery (IMA) and saphenous vein (SV) incubated for 30 min with inhibitors of mPGES-1 or COX-2 were investigated under normal and inflammatory conditions.

KEY RESULTS:

In inflammatory conditions, mPGES-1 and COX-2 proteins were more expressed, and increased levels of PGE2 and PGI2 were released. COX-2 and NOS inhibitors increased noradrenaline induced vascular contractions in IMA under inflammatory conditions while no effect was observed in SV. Interestingly, the mPGES-1 inhibitor significantly reduced (30-40%) noradrenaline-induced contractions in both vessels. This effect was reversed by an IP (PGI2 receptor) antagonist but not modified by NOS inhibition. Moreover, PGI2 release was increased with the mPGES-1 inhibitor and decreased with the COX-2 inhibitor, while both inhibitors reduced PGE2 release.

CONCLUSIONS AND IMPLICATIONS:

In contrast to COX-2 inhibition, inhibition of mPGES-1 reduced vasoconstriction by increasing PGI2 synthesis. Targeting mPGES-1 could provide a lower risk of cardiovascular side effects, compared with those of the COX-2 inhibitors.

LINKED ARTICLES:

This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.

PMID:
28675448
PMCID:
PMC5660006
DOI:
10.1111/bph.13939
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center